|
[1]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[2]KUMAR M,SARIN SK,HISSAR S,et al.Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J].Gastroenterology,2008,134(5):1376-1384.
|
|
[3]GUI HL,WANG H,YANG YH,et al.Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J].J Viral Hepat,2010,17(Suppl 1):44-50.
|
|
[4]LAI M,HYATT BJ,NASSER I,et al.The clinical significance of persistently normal ALT in chronic hepatitis B infection[J].J Hepatol,2007,47(6):760-767.
|
|
[5]RASTOGI A,MAIWALL R,BIHARI C,et al.Cirrhosis histology and Laennec staging system correlate with high portal pressure[J].Histopathology,2013,62(5):731-741.
|
|
[6]KIM MY,CHO MY,BAIK SK,et al.Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension[J].J Hepatol,2011,55(5):1004-1009.
|
|
[7]CALVARUSO V,BURROUGHS AK,STANDISH R,et al.Computer-assisted image analysis of liver col agen:relationship to Ishak scoring and hepatic venous pressure gradient[J].Hepatology,2009,49(4):1236-1244.
|
|
[8]XU S,WANG Y,TAI DC,et al.qF ibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].J Hepatol,2014,61(2):260-269.
|
|
[9]CHEN Y,PENG J,HOU J.Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B[J].Hepatol Int,2013,7(2):356-368.
|
|
[10]European Association for Study of Liver;Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol,2015,63(1):237-264.
|
|
[11]Review Panel for Liver Stiffness Measurement.Recommendations for the clinical application of transient elastography in liver fibrosis assessment[J].Chin J Hepatol,2013,21(6):420-424.(in Chinese)肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013,21(6):420-424.
|
|
[12]CHEN YP,LIANG XE,ZHANG Q,et al.Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J].J Gastroenterol Hepatol,2012,27(7):1219-1226.
|
|
[13]LIANG XE,DAI L,YANG SL,et al.Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection[J].Dig Liver Dis,2016,48(5):512-518.
|
|
[14]LIANG XE,ZHONG C,HUANG L,et al.Stepwise application of transient elastography and routine biomarkers optimizes hepatitis B cirrhosis detection[J].J Gastroenterol Hepatol,2016.[Epub ahead of print]
|
|
[15]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Long-term therapy with adefovir dipivoxil for HBeA g-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751.
|
|
[16]MARCELLIN P,CHANG TT,LIM SG,et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2008,48(3):750-758.
|
|
[17]MARCELLIN P,GANE E,BUTI M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.
|
|
[18]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(3):886-893.
|
|
[19]FUNG J,LAI CL,WONG DK,et al.Significant changes in liver stiffness measurements in patients with chronic hepatitis B:3-year follow-up study[J].J Viral Hepat,2011,18(7):e200-e205.
|
|
[20]OSAKABE K,ICHINO N,NISHIKAWA T,et al.Reduction of liver stiffness by antiviral therapy in chronic hepatitis B[J].J Gastroenterol,2011,46(11):1324-1334.
|
|
[21]WONG GL,WONG VW,CHOI PC,et al.On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients[J].Antivir Ther,2011,16(2):165-172.
|
|
[22]KIM BK,OH HJ,PARK JY,et al.Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy[J].Liver Int,2013,33(2):180-189.
|
|
[23]KIM MN,KIM SU,PARK JY,et al.Risk assessment of liverrelated events using transient elastography in patients with chronic hepatitis B receiving entecavir[J].J Clin Gastroenterol,2014,48(3):272-278.
|
|
[24]LEE HW,YOO EJ,KIM BK,et al.Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J].Am J Gastroenterol,2014,109(8):1241-1249.
|
|
[25]MAURICE J,BRODKIN E,ARNOLD F,et al.Validation of the baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices[J].J Hepatol,2016.[Epub ahead of print]
|
|
[26]WONG GL,CHAN HL,WONG CK,et al.Liver stiffnessbased optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J].J Hepatol,2014,60(2):339-345.
|
|
[27]JUNG KS,KIM SU,AHN SH,et al.Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroS can)[J].Hepatology,2011,53(3):885-894.
|
|
[28]de LEDINGHEN V,VERGNIOL J,BARTHE C,et al.Noninvasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus[J].Aliment Pharmacol Ther,2013,37(10):979-988.
|
|
[29]WANG JH,YEN YH,YAO CC,et al.Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy[J].Liver Int,2016.[Epub ahead of print]
|
DownLoad: